is being presented by Richard C. Smith & John E. Kelly, Partners, with Fulbright & Jaworski LLP and airs on Thursday, April 14th, 2011. For more details, or to register please visit our site at www.fxconferences.com
The U.S. Department of Justice (DOJ) leadership has announced at every opportunity that it is targeting the health care industry for FCPA violations, with a particular focus on pharmaceutical and medical device companies. In 2010, the DOJ followed through on its warnings to the health care industry by notifying at least a dozen pharmaceutical companies that they were under investigation for potential FCPA violations. While FCPA compliance is complex for all industries, the health care industry faces unique FCPA compliance challenges.
This presentation provides an overview of the U.S. Foreign Corrupt Practices Act, as well as other anti-bribery statutes like the new UK Bribery Act, and discusses the impact they have on companies doing business on a global scale. Our speakers review some of the recent investigations and enforcement trends in the life sciences industry, and suggest strategies for mitigating the risk associated with global business practices.
